The Shape-Shifting Nature of Multiple Myeloma and the Hope in Genomic Breakthroughs
I recently took a deep dive into some of the scientific abstracts from the ASH conference, and let me tell you, it was like entering a different universe, one where genes, mutations, and complex terms I had never heard of were flying at me left and right. As someone who’s been living with multiple myeloma (MM), I wanted to better understand the cutting-edge research and what it means for us patients. While I can’t claim to fully comprehend everything I read (many of the abstracts went way over my head), one thing became very clear: the disease MM is a bit like a shapeshifter. And when reading the research abstracts slowly and methodically one can pull out one consistent thread…each genomic mutation/variation/depletion/gain is being closely looked at and evaluated to see how they can be interpreted and manipulated to achieve better outcomes for MM patients!
I will not even try to interpret all I have read but I would like to share a sample of my process and my attempt to comprehend. I read the abstract: 250 Increased Expression of the Sialyltransferase Gene ST3GAL1 Predicts Lack of Sustained MRD Negativity and Increased Risk of Progression in Newly Diagnosed, Transplant Eligible Multiple Myeloma Patients in the Maintenance/Observation Phase of Cassiopeia Study
After reading through it slowly, I could piece together that the Sialyltransferase Gene (ST3GAL1) seems to play a role in MM progression. Specifically, increased expression of this gene is linked to a higher risk of relapse and lower progression-free survival. In other words, it’s one of those genetic markers that can predict how well a patient might do in the long term after treatment. The paper suggests that investigating desialylation strategies, or ways to reverse the effects of this gene, could be a promising area for future research. To a patient, this is incredibly encouraging! Not only are scientists working on new treatments, but they’re also looking at how to make current treatments work longer and more effectively.
The intensity and depth of this research is mind-boggling, and as stated above, although I can’t pretend to fully understand all the complexities of this research, I’m filled with hope. Every gene, mutation, and variation being studied is a potential pathway to better treatments for those of us living with multiple myeloma. So, while it may seem daunting to dive into these abstracts, I encourage my fellow patients to take a closer look. The future is full of promise, and the breakthroughs on the horizon could very well lead to a world where MM is no longer as unpredictable or devastating.
January 5, 2025
Terry Glassman @terryglassman